TY - JOUR
T1 - In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome
AU - Cioppi, Francesca
AU - Orioli, Tommaso
AU - Cantini, Giulia
AU - Ercolino, Tonino
AU - Cioppi, Federica
AU - Assié, Guillaume
AU - Jouinot, Anne
AU - Dedonno, Anna Aurora
AU - Santi, Raffaella
AU - de Krijger, Ronald R.
AU - Maggi, Mario
AU - Benelli, Matteo
AU - Canu, Letizia
AU - Nesi, Gabriella
AU - Luconi, Michaela
N1 - © 2026. The Author(s).
PY - 2026/3/10
Y1 - 2026/3/10
N2 - Adrenal lesions often occur in patients with multiple endocrine neoplasia type 1 (MEN1), mostly adrenal cortical adenomas (ACAs), although the frequency of adrenal cortical carcinomas (ACCs) is higher than in the general population. The coexistence of benign and malignant masses has seldom been documented, leaving open the question of ACC progression from benign forms. We report a comprehensive genetic characterization of three adrenal cortical tumor samples obtained from a familial MEN1 patient, operated for the rapid progression of an initially stable nonfunctional adrenal incidentaloma. Histologically, the tumor consisted of a small ACA contiguous to a large ACC, which subsequently relapsed. Exome sequencing of ACC, ACA and recurrence evidenced a MEN1 loss of heterozygosity (LOH) in ACC but not in ACA, where, however, a second hit driven by alternative mechanisms could not be excluded. The majority of the ACA variants were found to co-occurred in ACC (n = 36/42) and were benign, except for two of unknown significance in KANK1 and REN genes, described as associated with renal cancer. Among variants shared between ACC and its recurrence (n = 69), 11 were Tier III, while 2 affecting TP53 and NF1 genes were pathogenic. Bioinformatic clonal evolution analysis identified one clone − characterized by TP53 and NF1 mutations − absent in ACA but present in ACC and recurrence, as well as 2 clones shared between ACA and ACC but lost in the recurrence. In conclusion, comparative Whole Exome Sequencing (WES) analysis of three adrenal tumors in a MEN1 patient suggests a possible relationship between malignant and benign lesions occurring in MEN1 patients, without, however, demonstrating any causal adenoma-to-carcinoma progression driven by MEN1 LOH. Overall, these data further suggest an increased risk of MEN1 patients to develop adrenocortical malignancy.
AB - Adrenal lesions often occur in patients with multiple endocrine neoplasia type 1 (MEN1), mostly adrenal cortical adenomas (ACAs), although the frequency of adrenal cortical carcinomas (ACCs) is higher than in the general population. The coexistence of benign and malignant masses has seldom been documented, leaving open the question of ACC progression from benign forms. We report a comprehensive genetic characterization of three adrenal cortical tumor samples obtained from a familial MEN1 patient, operated for the rapid progression of an initially stable nonfunctional adrenal incidentaloma. Histologically, the tumor consisted of a small ACA contiguous to a large ACC, which subsequently relapsed. Exome sequencing of ACC, ACA and recurrence evidenced a MEN1 loss of heterozygosity (LOH) in ACC but not in ACA, where, however, a second hit driven by alternative mechanisms could not be excluded. The majority of the ACA variants were found to co-occurred in ACC (n = 36/42) and were benign, except for two of unknown significance in KANK1 and REN genes, described as associated with renal cancer. Among variants shared between ACC and its recurrence (n = 69), 11 were Tier III, while 2 affecting TP53 and NF1 genes were pathogenic. Bioinformatic clonal evolution analysis identified one clone − characterized by TP53 and NF1 mutations − absent in ACA but present in ACC and recurrence, as well as 2 clones shared between ACA and ACC but lost in the recurrence. In conclusion, comparative Whole Exome Sequencing (WES) analysis of three adrenal tumors in a MEN1 patient suggests a possible relationship between malignant and benign lesions occurring in MEN1 patients, without, however, demonstrating any causal adenoma-to-carcinoma progression driven by MEN1 LOH. Overall, these data further suggest an increased risk of MEN1 patients to develop adrenocortical malignancy.
KW - ACC and ACA
KW - Clonal evolution
KW - MEN1
KW - Molecular profiling
KW - Somatic mutations
KW - Whole Exome Sequencing
KW - Adrenal Cortex Neoplasms/genetics
KW - Adrenocortical Carcinoma/genetics
KW - Humans
KW - Middle Aged
KW - Male
KW - Multiple Endocrine Neoplasia Type 1/genetics
KW - Loss of Heterozygosity
KW - Adrenocortical Adenoma/genetics
KW - Female
KW - Adult
KW - Neoplasms, Multiple Primary/genetics
UR - https://www.scopus.com/pages/publications/105033211397
U2 - 10.1007/s12022-026-09908-0
DO - 10.1007/s12022-026-09908-0
M3 - Article
C2 - 41806143
AN - SCOPUS:105033211397
SN - 1046-3976
VL - 37
JO - Endocrine Pathology
JF - Endocrine Pathology
IS - 1
M1 - 14
ER -